PT3334747T - Formulação de gonadotrofina líquida estável - Google Patents
Formulação de gonadotrofina líquida estávelInfo
- Publication number
- PT3334747T PT3334747T PT167577808T PT16757780T PT3334747T PT 3334747 T PT3334747 T PT 3334747T PT 167577808 T PT167577808 T PT 167577808T PT 16757780 T PT16757780 T PT 16757780T PT 3334747 T PT3334747 T PT 3334747T
- Authority
- PT
- Portugal
- Prior art keywords
- antigen
- binding proteins
- depth filtration
- charged depth
- charged
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 238000011118 depth filtration Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44791—Microapparatus
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562204831P | 2015-08-13 | 2015-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3334747T true PT3334747T (pt) | 2023-12-12 |
Family
ID=56802689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT167577808T PT3334747T (pt) | 2015-08-13 | 2016-08-12 | Formulação de gonadotrofina líquida estável |
Country Status (15)
Country | Link |
---|---|
US (2) | US11098079B2 (pt) |
EP (2) | EP3334747B1 (pt) |
JP (1) | JP6889149B2 (pt) |
DK (1) | DK3334747T3 (pt) |
ES (1) | ES2964640T3 (pt) |
FI (1) | FI3334747T3 (pt) |
HR (1) | HRP20231544T1 (pt) |
HU (1) | HUE064252T2 (pt) |
LT (1) | LT3334747T (pt) |
MA (1) | MA42613A (pt) |
PL (1) | PL3334747T3 (pt) |
PT (1) | PT3334747T (pt) |
SG (1) | SG10202101105XA (pt) |
SI (1) | SI3334747T1 (pt) |
WO (1) | WO2017027861A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
CN107973487B (zh) * | 2017-11-14 | 2021-03-02 | 东华大学 | 一种染整废水层级处理工艺及装置 |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
AU2021208515A1 (en) * | 2020-01-15 | 2022-08-04 | F. Hoffmann-La Roche Ag | Methods to decrease impurities from recombinant protein manufacturing processes |
CN111410688A (zh) * | 2020-03-13 | 2020-07-14 | 苏州智享众创孵化管理有限公司 | 一种提高双特异性抗体纯度的分离纯化方法 |
AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US5237054A (en) | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6214221B1 (en) | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
AUPQ599700A0 (en) | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
EP2116265B1 (en) | 2000-10-12 | 2020-12-23 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
NZ529267A (en) | 2001-05-11 | 2006-05-26 | Amgen Inc | Peptides and related molecules that bind to tall-1 |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
SG2011076551A (en) | 2001-06-26 | 2015-08-28 | Amgen Inc | Antibodies to opgl |
WO2003017935A2 (en) | 2001-08-23 | 2003-03-06 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Igg抗体の安定な液体医薬製剤 |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
PL377091A1 (pl) | 2002-09-06 | 2006-01-23 | Amgen, Inc. | Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych |
WO2004034988A2 (en) | 2002-10-16 | 2004-04-29 | Amgen Inc. | Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors |
DK3284753T3 (da) | 2002-10-17 | 2021-07-05 | Genmab As | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
WO2004058988A2 (en) | 2002-12-20 | 2004-07-15 | Amgen, Inc. | Binding agents which inhibit myostatin |
RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
US7157276B2 (en) | 2003-06-20 | 2007-01-02 | Biogen Idec Inc. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
EP2364728A1 (en) | 2003-07-15 | 2011-09-14 | Amgen, Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
EP3673919A1 (en) | 2005-06-14 | 2020-07-01 | Amgen Inc. | Self-buffering protein formulations |
BRPI0616242A2 (pt) | 2005-09-15 | 2011-06-14 | Wyeth Corp | floculaÇço de proteÍna usando sais |
WO2008036899A2 (en) * | 2006-09-22 | 2008-03-27 | Amgen Inc. | Methods for removing viral contaminants during protein purification |
US20100056759A1 (en) * | 2006-10-19 | 2010-03-04 | Tolerx, Inc. | Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations |
PT3597659T (pt) | 2007-07-09 | 2023-04-04 | Genentech Inc | Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
DE102008037678A1 (de) * | 2008-08-14 | 2010-02-25 | Sartorius Stedim Biotech Gmbh | Tiefenfilterschicht mit anorganischem Schichtdoppelhydroxid |
SG10201702922VA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Isolation and purification of antibodies using protein a affinity chromatography |
AU2010243551B2 (en) * | 2009-04-30 | 2015-03-26 | Ablynx Nv | Method for the production of domain antibodies |
DK3037104T3 (da) | 2009-10-20 | 2020-07-20 | Abbvie Inc | Isolering og renselse af anti-il-13 antistoffer ved brug af protein a beslægtet kromatografi |
WO2011049798A1 (en) | 2009-10-20 | 2011-04-28 | Merck Sharp & Dohme Corp. | Use of mixed mode chromatography for the capture and purification of basic antibody products |
GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
WO2011140405A1 (en) * | 2010-05-07 | 2011-11-10 | Millipore Corporation | Enhanced clarification media |
SG10201503899SA (en) | 2010-05-18 | 2015-06-29 | Abbvie Inc | Apparatus And Process Of Purification Of Proteins |
JP6023715B2 (ja) * | 2010-10-11 | 2016-11-09 | アッヴィ・バハマズ・リミテッド | タンパク質の精製方法 |
US20130273607A1 (en) * | 2010-10-20 | 2013-10-17 | Medimmune, Llc | Methods for processing inclusion bodies |
US20120238730A1 (en) | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
DK2732021T3 (da) | 2011-07-08 | 2020-07-27 | Emd Millipore Corp | Forbedrede dybdefiltre til bioteknologiske engangsfremgangsmåder |
FR2977893B1 (fr) | 2011-07-11 | 2015-02-20 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre d'immunoglobulines polyvalentes |
HUE035941T2 (en) | 2011-08-02 | 2018-05-28 | Baxalta GmbH | Systems and Methods for Recombinant Production Methods to Increase Protein Yield |
WO2013028330A2 (en) * | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
AU2012355356B2 (en) | 2011-12-22 | 2017-10-12 | Genentech, Inc. | Ion exchange membrane chromatography |
US20140154270A1 (en) | 2012-05-21 | 2014-06-05 | Chen Wang | Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography |
WO2013177118A2 (en) * | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
ES2929876T3 (es) * | 2012-12-20 | 2022-12-02 | Medimmune Ltd | Replegamiento y purificación de moxetumomab pasudotox |
KR20160012975A (ko) | 2013-06-04 | 2016-02-03 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 정제 프로세스 |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
GB201318840D0 (en) | 2013-10-24 | 2013-12-11 | Univ Leeds | Method and device for protein preparation |
US20160272674A1 (en) * | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
CN106164086A (zh) | 2014-02-27 | 2016-11-23 | 新加坡科技研究局 | 抗体纯化方法 |
US20170191101A1 (en) | 2014-03-17 | 2017-07-06 | Regeneron Pharmaceuticals, Inc. | Clarification of mammalian cell culture |
WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
US20160176921A1 (en) * | 2014-12-22 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
-
2016
- 2016-08-12 WO PCT/US2016/046929 patent/WO2017027861A1/en active Application Filing
- 2016-08-12 HU HUE16757780A patent/HUE064252T2/hu unknown
- 2016-08-12 JP JP2018506988A patent/JP6889149B2/ja active Active
- 2016-08-12 MA MA042613A patent/MA42613A/fr unknown
- 2016-08-12 ES ES16757780T patent/ES2964640T3/es active Active
- 2016-08-12 PL PL16757780.8T patent/PL3334747T3/pl unknown
- 2016-08-12 HR HRP20231544TT patent/HRP20231544T1/hr unknown
- 2016-08-12 EP EP16757780.8A patent/EP3334747B1/en active Active
- 2016-08-12 LT LTEPPCT/US2016/046929T patent/LT3334747T/lt unknown
- 2016-08-12 DK DK16757780.8T patent/DK3334747T3/da active
- 2016-08-12 FI FIEP16757780.8T patent/FI3334747T3/fi active
- 2016-08-12 SI SI201631774T patent/SI3334747T1/sl unknown
- 2016-08-12 PT PT167577808T patent/PT3334747T/pt unknown
- 2016-08-12 US US15/751,231 patent/US11098079B2/en active Active
- 2016-08-12 SG SG10202101105XA patent/SG10202101105XA/en unknown
- 2016-08-12 EP EP22211542.0A patent/EP4209499A1/en active Pending
-
2021
- 2021-07-28 US US17/386,692 patent/US20210363180A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2964640T3 (es) | 2024-04-08 |
SG10202101105XA (en) | 2021-03-30 |
US11098079B2 (en) | 2021-08-24 |
JP2018526357A (ja) | 2018-09-13 |
WO2017027861A1 (en) | 2017-02-16 |
SI3334747T1 (sl) | 2024-02-29 |
EP3334747A1 (en) | 2018-06-20 |
US20180230180A1 (en) | 2018-08-16 |
MA42613A (fr) | 2018-06-20 |
JP6889149B2 (ja) | 2021-06-18 |
DK3334747T3 (da) | 2023-12-11 |
HUE064252T2 (hu) | 2024-02-28 |
EP4209499A1 (en) | 2023-07-12 |
HRP20231544T1 (hr) | 2024-03-15 |
LT3334747T (lt) | 2023-12-27 |
US20210363180A1 (en) | 2021-11-25 |
PL3334747T3 (pl) | 2024-04-02 |
FI3334747T3 (fi) | 2023-11-30 |
EP3334747B1 (en) | 2023-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285366A (en) | Multi-specific antigen-binding proteins | |
IL263690A (en) | Purification of multispecific antibodies | |
HK1253235A1 (zh) | 抗tigit抗原結合蛋白及其使用方法 | |
HK1231400A1 (zh) | 蛋白質的選擇性還原 | |
IL251125A0 (en) | Methods for the separation of diastereoisomers of gemcitabine-phosphate | |
SG10202101105XA (en) | Charged depth filtration of antigen-binding proteins | |
ZA201808524B (en) | Methods of affecting separation | |
IL248697A0 (en) | Methods for purifying antibodies | |
GB201604627D0 (en) | Improved method of FT-IMS | |
IL272670A (en) | Preparation of micro-electrodes | |
SG10202007893TA (en) | Methods of immunotherapy | |
IL252712A0 (en) | Method for protein production | |
IL248694A0 (en) | Nanoencapsulation of antigen binding molecules | |
HK1223624A1 (zh) | 替諾福韋的固體形式 | |
GB201609314D0 (en) | Methods of forming compounds | |
TWM533475U (en) | Improved structure of filter | |
GB201508443D0 (en) | Methods of identifying USP-binding compounds |